A retrospective comparison between regorafenib and TAS-102 for refractory metastatic colorectal cancer.

被引：0
|
作者：
Masuishi, Toshiki
Taniguchi, Hiroya
Hamauchi, Satoshi
Komori, Azusa
Kito, Yosuke
Mitani, Seiichiro
Hasegawa, Hiroko
Narita, Yukiya
Kadowaki, Shigenori
Ura, Takashi
Ando, Masashi
Mori, Keita
Tajika, Masahiro
Yasui, Hirofumi
Muro, Kei
Yamazaki, Kentaro
机构：
[1] Aichi Canc Ctr Hosp, Dept Clin Oncol, Nagoya, Aichi 464, Japan
[2] Shizuoka Canc Ctr, Div Gastrointestinal Oncol, Shizuoka, Japan
[3] Aichi Canc Ctr Hosp, Nagoya, Aichi 464, Japan
[4] Shizuoka Canc Ctr Hosp, Clin Res Ctr, Shizuoka, Japan
[5] Aichi Canc Ctr Hosp, Dept Endoscopy, Nagoya, Aichi 464, Japan
[6] Shizuoka Canc Ctr, Shizuoka, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 04期
关键词：
D O I：
10.1200/jco.2016.34.4_suppl.723
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
723
引用
收藏
页数：1
相关论文
共 50 条
  • [41] A phase II study of guadecitabine combined with irinotecan vs regorafenib or TAS-102 in irinotecan-refractory metastatic colorectal cancer patients
    Lee, Valerie
    Parkinson, Rose
    Zahurak, Marianna
    Cope, Leslie
    Cercek, Andrea
    Verheul, Henk
    Gootjes, Elske
    Lenz, Heinz Josef
    Iqbal, Syma
    Jones, Peter
    Baylin, Stephen
    Rami, Vandna
    Ahuja, Nita
    El Khoueiry, Anthony
    Azad, Nilofer S.
    INTERNATIONAL JOURNAL OF CANCER, 2024, 154 (10) : 1794 - 1801
  • [42] TAS-102 plus bevacizumab in metastatic colorectal cancer Reply
    Pfeiffer, Per
    Moller, Soren
    Winther, Stine Braendegaard
    Qvortrup, Camilla
    LANCET ONCOLOGY, 2020, 21 (05): : E227 - E227
  • [43] Genetic variants of ATM and XRCC3 to predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer.
    Suenaga, Mitsukuni
    Schirripa, Marta
    Cao, Shu
    Zhang, Wu
    Yang, Dongyun
    Berger, Martin D.
    West, Jordan David
    Ning, Yan
    Salvatore, Lisa
    Rossini, Daniele
    Antoniotti, Carlotta
    Inoue, Ramu
    Matsusaka, Satoshi
    Okazaki, Satoshi
    Miyamoto, Yuji
    Hanna, Diana L.
    Barzi, Afsaneh
    Loupakis, Fotios
    Lenz, Heinz-Josef
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [44] Erratum to: Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer
    Johanna C. Bendell
    Lee S. Rosen
    Robert J. Mayer
    Jonathan W. Goldman
    Jeffrey R. Infante
    Fabio Benedetti
    Donghu Lin
    Hirokazu Mizuguchi
    Christopher Zergebel
    Manish R. Patel
    Cancer Chemotherapy and Pharmacology, 2016, 77 : 439 - 439
  • [45] TAS102 in combination with oxaliplatin (TASOX) for refractory metastatic colorectal cancer.
    Li, Sharon
    Ling, Fan
    Misdary, Christian
    Liu, Hao
    DiRubbo, Manda
    Boland, Patrick M.
    Berim, Lyudmyla Derby
    Gulhati, Pat
    Cohen, Seth D.
    Taff, Jessica Leland
    Shah, Ankit
    Lee, Patrick
    Radovich, Delia
    Leitner, Stuart P.
    Scoppetuolo, Michael
    Hochster, Howard S.
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 189 - 189
  • [46] Both regorafenib and TAS-102 give metastatic colorectal cancer patients survival benefit with different toxicity profile
    Sugimoto, Naotoshi
    Yoshinami, Tetsuhiro
    Yamamoto, Sachiko
    Yagi, Toshinari
    Imamura, Fumio
    ANNALS OF ONCOLOGY, 2015, 26 : 100 - 100
  • [47] Cost-effectiveness of TAS-102 plus bevacizumab versus TAS-102 monotherapy in patients with metastatic colorectal cancer
    Kiyoaki Sugiura
    Yuki Seo
    Takayuki Takahashi
    Hideyuki Tokura
    Yasuhiro Ito
    Motomu Tanaka
    Norihiro Kishida
    Yusuke Nishi
    Yoshihiko Onishi
    Hikaru Aoki
    BMC Gastroenterology, 21
  • [48] Cost-effectiveness of TAS-102 plus bevacizumab versus TAS-102 monotherapy in patients with metastatic colorectal cancer
    Sugiura, Kiyoaki
    Seo, Yuki
    Takahashi, Takayuki
    Tokura, Hideyuki
    Ito, Yasuhiro
    Tanaka, Motomu
    Kishida, Norihiro
    Nishi, Yusuke
    Onishi, Yoshihiko
    Aoki, Hikaru
    BMC GASTROENTEROLOGY, 2021, 21 (01)
  • [49] Impact of regorafenib dose optimization on clinical outcomes compared to best supportive care and TAS-102 in the treatment of relapsed/refractory metastatic colorectal cancer
    Bekaii-Saab, T.
    Burnett, H.
    Proskorovsky, I.
    Yoon, S.
    Wang, Y.
    Ostojic, H.
    Gaianu, L.
    Su, Y.
    ANNALS OF ONCOLOGY, 2022, 33 : S262 - S262
  • [50] Retrospective study of TAS-102 plus bevacizumab for patients with metastatic colorectal cancer in salvage therapy
    Hisamatsu, A.
    Ikusue, T.
    Toshima, H.
    Kobayashi, K.
    Shimada, K.
    ANNALS OF ONCOLOGY, 2019, 30
12345